Molecular Bases of Disease: Characterization of Conformation-dependent Prion Protein Epitopes

Hae-Eun Kang, Chu Chun Weng, Eri Saijo, Vicki Saylor, Jifeng Bian, Sehun Kim, Laylaa Ramos, Rachel Angers, Katie Langenfeld, Vadim Khaychuk, Carla Calvi, Jason Bartz, Nora Hunter and Glenn C. Telling

doi: 10.1074/jbc.M112.395921 originally published online September 4, 2012

Access the most updated version of this article at doi: 10.1074/jbc.M112.395921

Find articles, minireviews, Reflections and Classics on similar topics on the JBC Affinity Sites.

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2012/09/04/M112.395921.DC1.html

This article cites 58 references, 26 of which can be accessed free at
http://www.jbc.org/content/287/44/37219.full.html#ref-list-1
Characterization of Conformation-dependent Prion Protein Epitopes*\textsuperscript{1,2}

Received for publication, June 27, 2012, and in revised form, August 28, 2012 Published, JBC Papers in Press, September 4, 2012, DOI 10.1074/jbc.M112.395921

Hae-Eun Kang\textsuperscript{1}, Chu Chun Weng\textsuperscript{3}, Eri Saijo\textsuperscript{1,9}, Vicki Saylor\textsuperscript{10}, Jifeng Bian\textsuperscript{11}, Sehun Kim\textsuperscript{12}, Layla Ramos\textsuperscript{13}, Rachel Angers\textsuperscript{14,15}, Katie Langenfeld\textsuperscript{16}, Vadim Khaychuk\textsuperscript{17}, Carla Calvi\textsuperscript{18}, Jason Bartz\textsuperscript{19}, Nora Hunter\textsuperscript{20}, and Glenn C. Telling\textsuperscript{21}

From the \textsuperscript{1}Prion Research Center, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado 80523, the \textsuperscript{2}Integrated Biomedical Sciences Program, Department of Microbiology, Immunology, and Molecular Genetics, Department of Neurology, and Sanders Brown Center on Aging, University of Kentucky Medical Center, Lexington, Kentucky 40536, the \textsuperscript{3}Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska 68178, and the \textsuperscript{4}Roslin Institute, University of Edinburgh, Easter Bush, Midlothian EH25 9RG, Scotland, United Kingdom

\textbf{Background:} Despite structural reorganization during disease, conformational prion protein epitopes remain undefined.

\textbf{Results:} We identify specific amino acids constituting novel conformational monoclonal antibody epitopes.

\textbf{Conclusion:} Immunoreactivities of globular domain epitopes depend on maintenance of regional tertiary structure.

\textbf{Significance:} Our studies address how denatured conformational epitopes remain functional, provide insights into normal and disease-related prion protein, and expand epitope tagging options.

Whereas prion replication involves structural rearrangement of cellular prion protein (PrPC), the existence of conformational epitopes remains speculative and controversial, and PrP transformation is monitored by immunoblot detection of PrP(27-30), a protease-resistant counterpart of the pathogenic scrapie form (PrP\textsuperscript{Sc}) of PrP. We now describe the involvement of specific amino acids in conformational determinants of novel monoclonal antibodies (mAbs) raised against randomly chimeric PrP. Epitope recognition of two mAbs depended on polymorphisms controlling disease susceptibility. Detection by one, referred to as PRC5, required alanine and asparagine at discontinuous mouse PrP residues 132 and 158, which acquire proximity when residues 126-218 form a structured globular domain. The discontinuous epitope of glycosylation-dependent mAb PRC7 also mapped within this domain at residues 154 and 185. In accordance with their conformational dependence, tertiary structure perturbations compromised recognition by PRC5, PRC7, as well as previously characterized mAbs whose epitopes also reside in the globular domain, whereas conformation-independent epitopes proximal or distal to this region were refractory to such destabilizing treatments. Our studies also address the paradox of how conformational epitopes remain functional following denaturing treatments and indicate that cellular PrP and PrP(27-30) both renature to a common structure that reconstitutes the globular domain.

\* This work was supported, in whole or in part, by National Institutes of Health Grants RO1 NS040334 and PO1 AI077774-015261 (to G. C. T.) and T32 DA022738 (to V. K., R. A., and G. C. T.).

\* This article contains supplemental Experimental Procedures and Figs. 1 and 2.

\*\textsuperscript{1} Present address: Dept. of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80523.

\*\textsuperscript{2} To whom correspondence should be addressed. Tel.: 970-491-2968; E-mail: glenn.telling@colostate.edu.

\*\textsuperscript{3} The abbreviations used are: CWD, chronic wasting disease; PrP, prion protein; PrP\textsuperscript{C}, cellular form of the prion protein; PrP\textsuperscript{Sc}, scrapie form of the prion protein; mAb, monoclonal antibody; PK, proteinase K; Tg, transgenic; RK13, rabbit kidney epithelial cells; PNGase F, peptide: \textsuperscript{-}glycosidase F; SPR, surface plasmon resonance; Rec, recombinant.


**Conformation-dependent PrP Epitopes**

originally observed in the brains of patients with Creutzfeldt-Jakob disease (4), and is subsequently shown to be calpain-dependent (5). PrPSc is cleaved between amino acids 110/111 to produce a 17-kDa carboxyl-terminal fragment referred to as C1 (4).

Because of the proteinaceous nature of prions, antibodies have been invaluable reagents for studying virtually all aspects of pathogenesis. The seminal observation that polyclonal antisera raised against PrP(27–30) (6) also reacted with PrP in uninfected brains (7) was instrumental in establishing the precursor-product relationship between the cellular and scrapie isoforms. Subsequent attempts to isolate anti-PrP monoclonal antibodies (mAbs) were not without significant challenges (6), in large part because the host does not mount an inflammatory response during prion infection. The availability of Prnp0/0 mice in which the PrP gene was ablated (8) circumvented the underlying immune tolerance to PrP, allowing the generation of various anti-PrP mAbs (9).

Definition of structural epitopes requires x-ray crystallography of anti-PrP mAb-antigen complexes (10, 11). Because this approach is laborious, ELISA-based peptide scanning has been the preferred method to map the approximate locations of epitopes. However, surprisingly few anti-PrP mAbs are amenable to this form of characterization, leading previous investigators to infer the existence of discontinuous PrP epitopes (12–17). To date, the involvement of specific amino acid residues in such hypothesized conformational epitopes has not been described. Moreover, this inference raises a conundrum (13), because all such antibodies bind PrP in Western blots, where PrP is defined by investigators as denatured (12, 13, 15, 18–22). We therefore set out to gain a better understanding of the involvement of specific amino acid residues in discontinuous, conformation-dependent PrP epitopes. We used a directed molecular evolution approach (23) to create shuffled genes expressing novel PrP epitopes, and by determining the reactivities of the resulting mAbs against a large panel of PrP primary structures and polymorphic variants thereof, we mapped and confirmed by mutational analysis the involvement of specific residues in epitope binding and PrPSc to PrPSc conversion.

**EXPERIMENTAL PROCEDURES**

**Transgenic Mice**—Transgenic (Tg) mice expressing mouse, deer, bovine, and sheep PrP were generated using the cosSHa. TcT cosmid vector (24). Tg mice expressing deer PrP with polymorphisms at residues 95 and 96, elk, and human PrP with valine or methionine polymorphisms at residue 129 (25) were generated using the MoPrP.Xho vector (26). Tg mice expressing horse PrP were produced using a modified MoPrP.Xho vector, referred to as pJB1, in which BsiWI and FseI sites replaced the XhoI site. All mice were maintained on an inbred Prnp0/0 FVB background (FVB/Prnp0/0).

**Generation of Chimeric PrP Coding Sequences by DNA Shuffling**—One hundred ng of recombinant pCAGGS vectors harboring elk or mouse PrP-coding sequences were amplified with Pfu polymerase (Stratagene, La Jolla, CA) using the following conditions: pre-denaturation 95 °C/3 min; 95 °C/40 s; 60 °C/40 s; and 72 °C/60 s. PCR products were mixed in an equal ratio, and 3 μg of total DNA was incubated at 15 °C for 10 min, followed by addition of 0.15 units of DNase I (Roche Applied Science), and a further incubation at 15 °C for 10 min. The reaction was terminated by adding 10 μl of stop solution and incubation at 96 °C for 10 min. DNase I-digested DNA was separated on a 2% low temperature agarose gel (Invitrogen), and fragments in the range of 10–300 bp were excised and extracted in phenol/chloroform. For re-assembly of small DNA fragments by PCR, 30 μl of DNase I-digested DNA fragments, 5 μl of Pfu Ultra buffer, 1 μl of dNTP (Roche Applied Science), and 1 μl of Pfu Ultra (Stratagene, La Jolla, CA) were mixed, and the volume was adjusted to 50 μl with distilled H2O. The re-assembly PCR was performed for 45 cycles using the following conditions: 94 °C/3 min; 94 °C/30 s (27 °C + 1 °C/cycles)/1 min; 72 °C/(1 min + 4 s/cycles). The PCR product was maintained at 72 °C for 10 min and then stored at 4 °C. Reassembled DNA fragments were amplified using primers recognizing 5’ and 3’ ends of the open reading frame containing added EcoRV and BamHI sites for 35 cycles using the following conditions: pre-denaturation 94 °C/3 min; 94 °C/45 s; 47 °C with increases of 0.7 °C/cycle 1 min; 72 °C/1 min. PCR products were held at 72 °C for 10 min. Shuffled DNA fragments were digested with BamHI and EcoRV (New England Biolabs), purified, and then inserted into pIRESpuro3 vector (Clontech). Following transformation of bacteria to antibiotic resistance, colonies were screened for recombinant plasmids by PCR. Plasmids were extracted from clones containing the correct sized recombinants using a QIA miniprep kit (Qiagen, Valencia), and plasmids were sequenced using a CEQ8000 (Beckman Coulter, Fullerton, CA).

**Preparation of Purified Recombinant PrP**—Selected shuffled DNA constructs were PCR-amplified and cloned into pET100/D-TOPO® (Invitrogen). Transformed BL21 Star™ (DE3) (Invitrogen) were cultured until the absorbance value reached 1.0 at 650 nm and induced using isopropyl-β-D-galactopyranoside (Sigma) at a final concentration of 1 mm. Bacteria were harvested after a 5-h incubation at 37 °C. Bacterial pellets were resuspended and lysed with Celllytic solution (Sigma) and centrifuged to obtain inclusion bodies, following solubilization with Celllytic IB solution (Sigma). Purification was performed using Ni-NTA column (Qiagen, Valencia) according to the manufacturer’s instructions. Purified protein was refolded by dialysis in 20 mM NaAc buffer (pH 4.5). The 6-histidine tag was removed by cleavage with enterokinase (Invitrogen). Protein content was determined by the bicinchoninic acid (BCA) assay (Pierce), and purity was assessed by SDS-PAGE followed by Coomassie Blue staining.

**Development and Cloning of Hybridoma Cells**—FVB/Prnp0/0 mice were immunized with 50 μg of purified recombinant PrP in Freund’s complete adjuvant by injection into the peritoneal cavity. Injections were repeated after 15, 30, and 45 days using 30 μg of antigen with Freund’s incomplete adjuvant. Finally, 3 days prior to fusion, mice received the same amount of antigen in PBS without adjuvant. Mice with the highest antibody titer were used in cell fusions. Harvested spleen cells were fused with P3X63.Ag8 myeloma cells (ATCC, TIB-9) at a ratio of 2:1 in DMEM (HyClone, Logan) with 50% (w/v) polyethylene glycol 1500 (Roche Applied Science). Hybridoma cells were selected in medium containing hypoxanthine/aminopterin/thymidine (HAT).
Characterization of Antibody Reactivity by ELISA—ELISA plates (NUNC, Rochester, NY) were coated with 100 μl of 1 μg/ml recombinant shuffled PrP solution and stored overnight at 4 °C. Plates were blocked with 200 μl of 3% bovine serum albumin in PBS, 0.05% Tween 20 for 2 h at 37 °C and washed three times with PBS, 0.05% Tween 20. Plates were incubated with 100 μl of conditioned medium from hybridoma cells for 2 h at 37 °C. After three PBS/Tween 20 washes, 100 μl of peroxidase-conjugated goat anti-mouse antibody (Sigma) at a dilution of 1:5000 was added, and the plates were incubated for 1 h at 37 °C, followed by three PBS/Tween 20 washes. Color development was accomplished by adding 100 μl of 2,2'-azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt peroxidase solution (KPL, Gaithersburg, MD) at room temperature in the dark. The color reaction was stopped by adding 100 μl of stop solution (KPL, Gaithersburg, MD), and the absorbance of samples was measured at 405 nm in an ELISA plate reader (ELx808, Bio-Tek Instruments, Winooski, VT). Isotyping was performed by ELISA using isotype-specific anti-immunoglobulin conjugates (Pierce).

Antibody Purification—Hybridoma cells were cultured in a 50:50 solution of complete DMEM and CDM4Mab (HyClone, Logan), which is a serum-free medium for the culture of hybridoma cells. After 1 week, the medium was collected, and cell debris was removed by centrifugation at 2000 × g for 10 min. Antibodies were purified by affinity chromatography using a HiTrap™ protein G column (GE Healthcare) and the Profinia™ protein purification system (Bio-Rad) with preprogrammed methods for antibody purification. Following equilibration of the protein G column with 20 mM sodium phosphate (pH 7.0) binding buffer, hybridoma culture medium was applied at a rate of 1 ml min⁻¹. After washing the column with binding buffer, antibodies were eluted with 0.1 M glycine-HCl (pH 2.7) that was neutralized by the addition of 50 μl of 1 M Tris-HCl (pH 9.0) per 1 ml of elution buffer.

Stable Transfection and Prion Infection of Cultured Cells—PrP coding sequences with or without mAb epitope mutations were synthesized (GenScript, Piscataway, NJ) with AflII and EcoRI restriction endonuclease recognition sites at the 5' and 3' ends, respectively. Digested amplicons were inserted into AflII- and EcoRI-cleaved pIRESpuro3 (Clontech). PrP expression cassettes containing in-frame deletions were generated by PCR-based mutagenesis using the QuikChange mutagenesis kit (Stratagene) according to the manufacturer’s instructions. Mutated constructs were sequenced using a CEQ 8000 (Beckman Coulter, Fullerton, CA). Rabbit kidney epithelial cells (RK13) were plated in 6-well plates 1 day prior to transfection. Transfection mixtures were prepared by mixing 2 μg of plasmid and 10 μl of Lipofectamine 2000 (Invitrogen) in 500 μl of Opti-MEM (Invitrogen). After 5 h, the transfection solution was exchanged with complete medium containing 10% FBS, followed by passage to 10-cm plates the next day. Transfected cells were selected in complete medium containing 1 μg/ml puromycin.

For infection, transfected cells (2 × 10⁵ cells/well) were plated in 6-well plates, and 0.2% brain homogenates in PBS were added to cell monolayers. After 5 h, 2 ml of complete medium was added, and cells were incubated for 5 days. After three passages, lysates of confluent cell monolayers were prepared in cold lysis buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 0.5% sodium deoxycholate, 0.5% Igepal CA-630) and analyzed by Western blotting.

Western Blotting—Brain homogenates were prepared in 10% (w/v) sterile PBS lacking Ca²⁺ and Mg²⁺ by repeated extrusion through 18- and then 21-gauge needles. Protein content in brain homogenates and cell lysates was determined by BCA (Pierce). Brain homogenates and cell lysates were digested with 100 or 30 μg/ml of proteinase K (PK), respectively (Roche Applied Science), in cold lysis buffer for 1 h at 37 °C. Digestion was terminated with phenylmethylsulfonyl fluoride at a final concentration of 2 μM. Deglycosylation of PrP was performed by treatment of PNGase F (New England Biolabs) for 3 h at 37 °C. Samples were prepared for SDS-PAGE either in the presence or absence of β-mercaptoethanol (βME) (Bio-Rad) and boiled for 10 min. Proteins were resolved by SDS-PAGE and transferred to polyvinylidene difluoride Immobilon (PVDF)-FL membranes (Millipore). Membranes were probed with primary mAbs followed by horseradish peroxidase-conjugated anti-mouse secondary antibody (GE Healthcare). Protein was visualized by chemiluminescence using ECL Plus (GE Healthcare) and an FLA-5000 scanner (Fujifilm Life Science, Woodbridge, CT).

Surface Plasmon Resonace (SPR) Measurements—SPR measurements were obtained with a Biacore T100 instrument (GE Healthcare). The surfaces of flow channels on a CM5 chip were activated with 1-ethyl-3-(3-dimethylaminopropyl)carbo diimide hydrochloride and N-hydroxysuccinimide. Recombinant mouse PrP or elk PrP was diluted to 20 μg/ml in 10 mM sodium acetate (pH 5.5) and immobilized on a channel of the activated CM5 sensor chip. After immobilization, all surfaces were blocked with 1 M ethanolamine hydrochloride (pH 8.5). Another channel of the chip was processed through an identical coupling procedure without addition of ligand recombinant PrP and was used as reference. All kinetic SPR analyses were run at a 10 μl/min PBS flow, and antibodies were injected at concentrations ranging from 50 to 3200 nM. Association or dissociation was recorded for 180 or 360 s, respectively. After each cycle, the surface was regenerated with 50 mM NaOH. Kinetic data were calculated using Biacore T100 evaluation software according to the bivalent analyte model.

Structural and Statistical Analyses—Three-dimensional structures of mouse PrP (3) were analyzed using the 2007 iMol Molecular Visualization Program. Statistical analyses were performed using 2010 Prism 5.0d for Mac OS X, GraphPad Software Inc.

RESULTS

Generation of Chimeric PrP by DNA Shuffling—Nucleotides within the mouse Prnp and cervid PRNP gene coding sequences share ~80% identity, and the primary structures of their translation products are ~85% identical. We recombined the coding sequences of mouse and elk PrP in vitro, using a PCR-based technique referred to as DNA shuffling (27), to produce a library of randomly chimeric PrP. DNA sequence analysis of 96 recombinant clones identified 34 different shuffled PrP sequences. Three chimeras, referred to as Mo/CerPrP-3,
Mo/CerPrP-34, and Mo/CerPrP-68, were selected for bacterial expression and recombinant (Rec) PrP purification.

Isolation of PRC Monoclonal Antibodies—High antibody titers resulted from immunization of Prnp0/0 mice with purified Rec PrP preparations. Following fusion of splenocytes from immunized mice with myeloma cells, we obtained two clones from Rec Mo/CerPrP-3 immunized mice, 25 clones from Rec Mo/CerPrP-68 immunized mice, and no clones from Rec Mo/CerPrP-34 immunized mice. Of the 25 clones from Rec Mo/CerPrP-68 immunized mice, 14 had reproducibly strong reactivity against Rec Mo/CerPrP-68 by ELISA and Western blotting. Ultimately, four mAbs, originally coded as 9E9, 5C6, 7H11, and 9H9 (28, 29), hereafter referred to as PRC (Prion Research Center) 1, 5, 7, and 9, respectively, were selected for further characterization. Hybridomas were cloned two additional times. Monoclonal antibody PRC5 is IgG2a, whereas mAbs PRC1, PRC7, and PRC9 are IgG1.

Epitope Characterization of PRC Monoclonal Antibodies—We determined the antigen binding properties of the PRC mAbs by probing Western blots of brain extracts from Tg mice expressing mouse, deer, elk, cattle, sheep, horse, or human PrP, as well as various species including Syrian, Chinese, and Armenian hamsters, mink, ferret, squirrel monkey, and cattle. Comparison of the reactive and nonreactive PrP primary structures with that of the shuffled Rec Mo/CerPrP-68 immunogen allowed us to identify specific amino acid residues that were critical for recognition by the various PRC mAbs. Of the 30 amino acid differences between mouse and elk PrP, recombinant Mo/CerPrP-68 shares 14 with mouse and 16 with elk PrP.

Monoclonal antibody PRC5 reacted with all primary structures tested except squirrel monkey PrP (Fig. 1A). However, reactivity with sheep PrP was dependent on the naturally occurring Ala/Val polymorphism at residue 136, because PRC5 also failed to react with in brain extracts from Tg mice expressing sheep PrP with Val at this position, referred to as OvPrP-V136 (Fig. 1A). Because squirrel monkey PrP contains Ala at the corresponding location (Fig. 1B), its failure to react with PRC5 (Fig. 1A) indicated that other amino acid(s), differing in this species also include the PRC5 epitope. Squirrel monkey PrP contains serine at residue 162, equivalent to residue 158 in mouse PrP, whereas Mo/CerPrP-68, and all other PrP species tested contain Asn at this position (Fig. 1B). No other amino acids differing between PRC5 reactive and nonreactive PrP primary structures correlated with antibody binding.

To confirm their role in the functional epitope of PRC5, we engineered constructs in which each of these two residues were individually mutated in mouse or elk PrP. Wild type and mutated constructs, referred to as MoPrP-V132, MoPrP-S158, ElkPrP-V133, and ElkPrP-S162, were stably expressed in RK13 cells, which do not express endogenous PrP (30). Consistent with a requirement for both residues in mAb recognition, mutation of either residue in each primary structure prevented detection by PRC5 (Fig. 1C).

Whereas mAb PRC7 also detected a wide range of PrP primary structures, it failed to react with cattle, human, or hamster PrP. Wild type and mutated constructs, referred to as MoPrP-V132, MoPrP-S158, ElkPrP-V133, and ElkPrP-S162, were stably expressed in RK13 cells, which do not express endogenous PrP (30). Consistent with a requirement for both residues in mAb recognition, mutation of either residue in each primary structure prevented detection by PRC5 (Fig. 1C). Whereas mAb PRC7 also detected a wide range of PrP primary structures, it failed to react with cattle, human, or hamster PrP (Fig. 2A). In addition, PRC7 preferentially reacted with aglycosyl and monoglycosyl but not diglycosyl PrP (Figs. 2, 6A, and 7). Although all reactive primary structures contain tyrosine at the position corresponding to residue 154 in mouse PrP, hamster species contain Asn, and cattle and human PrP contain histidine (Fig. 2B). To confirm the requirement of this residue in recognition by PRC7, we changed Tyr at residue 154 in Mo/CerPrP-68.
mouse PrP to Asn, and changed Asn at the corresponding residue in Syrian hamster PrP to Tyr. Mutant and wild type constructs were stably expressed in RK13 cells, and Western blotted extracts were probed with PRC7 (Fig. 2C). Consistent with a requirement for Tyr at residue 154 in mouse PrP in mAb recognition, mutation to Asn prevented detection by PRC7, whereas mutation of Asn to Tyr at position 155 in Syrian hamster PrP allowed detection by PRC7 (Fig. 2C). We also mutated His to Tyr at position 166 in cattle PrP, which corresponds to position 154 in mouse PrP, but this mutation failed to confer reactivity to PRC7 (Fig. 2C). Cattle PrP uniquely contains glutamic acid at position 197 instead of glutamine, which is conserved in all other species (Fig. 2B). To address whether this residue also partakes in PRC7 recognition, we changed the corresponding mouse PrP residue Gln-185 to Glu. This mutation, either singly or in combination with Asn-154, prevented recognition by PRC7, whereas reversal of both Asn to Tyr and Glu to Gln at the corresponding residues 166 and 197 in cattle PrP allowed detection by PRC7. We conclude that mouse PrP residues 154 and 185 participate in PRC7 recognition. No other amino acid differences between PRC7-reactive and nonreactive PrP species correlated with antibody binding.

Conservation of Gln at this position between reactive and nonreactive species (Fig. 3B) demonstrated that additional primary structural elements controlled PRC1 binding. Although species that failed to react with PRC1 contained three consecutive Gly residues immediately following this Gln, reactive species contained only two (Fig. 3B), suggesting that the number of Gly residues at this location controlled recognition by PRC1. To address this, we created mutated mouse and elk PrP coding sequences, referred to as MoPrP-2G and ElkPrP-3G, in which the number of Gly residues was changed from three to two in the mouse PrP sequence and from two to three in elk PrP. Mutant and wild type constructs were stably expressed in RK13 cells, and Western blotted extracts were probed with PRC1. Each construct had the expected reactivity with PRC1 as follows: deletion of one of the three Gly residues between 91 and 93 in mouse PrP conferred susceptibility to MoPrP-2G, whereas insertion of an additional Gly residue at the corresponding location in elk PrP abolished detection in ElkPrP-3G (Fig. 3C). Immunoblot probing with mAb 6H4 confirmed transgene expression in all cases. Consistent with this epitope location, PRC1 detected full-length elk PrP, C2, and PrP(27–30) but failed to react with C1 following PNGase F-mediated removal of N-linked glycans; in contrast, mAb 6H4 detected full-length mouse and elk PrP, and both endogenously cleaved fragments (Fig. 3D).

FIGURE 2. Functional epitope of mAb PRC7. A, Western blot reactivity with various PrP primary structures. Samples from hamsters, mink, ferret, and squirrel monkey were prion infected. Syr., Syrian; Chin., Chinese; and Arm., Armenian hamsters; Sq. Mon., squirrel monkey. B, primary structures are aligned between mouse PrP residues 152 and 198. Reactive species are boxed and shaded red. Glycans attached at residues 180 and 196 are shown as green hexagons. Residues 154 and 185 are boxed and shaded blue, and side chains are yellow in the tertiary structure. C, Western blots of RK13 cell extracts transfected with the following: Mo N154, mouse PrP with Asn at residue 154; Mo E185, mouse PrP with Glu at residue 185; Mo N154/E185, mouse PrP with Asn at residue 154 and Glu at residue 185; Sha wt, wild type Syrian hamster PrP; Sha Y155, Syrian hamster PrP with Tyr at residue 155; Bo wt, wild type cattle PrP; Bo Y166, cattle PrP with Tyr at residue 166; Bo Y166/Q197, cattle PrP with Tyr at residue 166, and Gln at residue 197.
Of the four PRC mAbs, PRC9 had the most restricted reactivity, responding only to mouse and hamster PrP (Fig. 4A). By comparing the PrP primary structures of Rec Mo/CerPrP-68 with those of reactive and nonreactive species, we located the PRC9 epitope within the C terminus of PrP (Fig. 4B). Mouse and hamster PrP primary structures contain aspartic acid and Gly residues at positions 226 and 227, whereas nonreactive species lacked these two adjacent residues. Expression of additional mouse PrP mutants in RK13 cells showed that PRC9 binding was inhibited by mutation of Tyr to Ala at residue 224, which is conserved in all tested species except horse, but not mutation of Tyr to Ala at residue 225 (Fig. 4B). Our results demonstrate that the PRC9 epitope overlaps the binding locations of recombinant R1 and R2 antibodies, which have been mapped to the region containing residues 224–230 (16). This region corresponds to the globular carboxy-terminal domain that contains regions of secondary structure, defined by NMR analyses as being composed of residues 126–218 (3) (Fig. 5A). PRC9 recognized all constructs harboring deletions outside this domain between 107–121 and 222–230 (Fig. 5B). In contrast to the behavior of PRC5 and PRC7, PRC9 satisfied our initial expectations because it reacted with all deletion constructs except MoPrP/H9004222–230, which contains its epitope (Fig. 5B). The reactivity of PRC9 also confirmed that compromised PRC5 and PRC7 binding to deletions between residues 122 and 222 was not the result of unstable mutant PrP expression in mammalian cells and bacteria. We obtained similar antibody reactivities when we expressed redacted constructs in bacteria and probed cell extracts with antibodies on Western blots (supplemental Fig. 1).

We next expanded our analyses to include previously characterized mAbs. The epitopes of 6H4 and D18 have previously been mapped to the region encompassing residues 132–156 of mouse PrP (Fig. 1B) (16, 31). Similar to the behavior of PRC5 and PRC7, deletions affecting regions of secondary structure between residues 126 and 218 also prevented or reduced detection by mAbs 6H4 and D18, whereas deletions within the
unstructured regions had no effect on immunodetection (Fig. 5B). These findings supported the notion that failure of PRC5 and PRC7 to bind deletions within the structured domain was not the result of undiscovered epitope-binding elements but rather that deletion mutations within the PrP globular domain perturb the correct tertiary structure of that region, and thus affect the topology of conformation-dependent epitopes of mAbs PRC5, PRC7, 6H4, and D18. In contrast to mAbs binding epitopes in the structured region, HumP, the epitope of which is adjacent to the PRC1-binding site (Fig. 3B) (32), and POM2, which binds mouse PrP at an adjacent location in the octapeptide repeat region (13), recognized all deletions and wild type PrP (Fig. 5B and supplemental Fig. 1), whereas R1 bound all constructs except MoPrP Δ222–230, which harbors its epitope (Fig. 5B).

Conformation-dependent Antibody Reactivities—The almost 30-residue separation between residues 132 and 158 demon-
strates that the epitope recognized by PRC5 is discontinuous. The adjacent proximity of residues 132 and 158 in the tertiary structure of PrP (Fig. 1B) (3) therefore indicates that PRC5 reactivity is dependent on PrP conformation. In previous studies, the inability to map the locations of epitopes by peptide scanning and reduced reactivity of the corresponding mAbs after disulfide bond reduction were cited as evidence that those epitopes were discontinuous and therefore that recognition depended on intact PrP tertiary structure (15). In keeping with these previous observations, reactivity of mAb PRC5 with mouse and cervid PrP on Western blots was increased 1.5-fold (p < 0.05) and 1.7-fold (p < 0.005) in the absence of βME (Fig. 6, A and B). Consistent with conformation-dependent reactivity of PRC7 involving discontinuous residues 154 and 185, immuno-detection of mouse PrP by PRC7 was increased 4-fold and with cervid PrP −12-fold (p < 0.01) under nonreducing conditions compared with reducing Western blotting conditions (Fig. 6, A and B). Surprisingly, because its binding has been mapped to a single sequential length of the polypeptide chain (31), mAb 6H4 reactivity with both cervid and mouse PrP was also increased 3-fold (p < 0.01) under nonreducing conditions (Fig. 6, A and B), indicating that its epitope also shares the property of conformational dependence with the discontinuous epitopes of PRC5 and PRC7. In accordance with the notion that PRC1 recognizes a conformation-independent epitope, reactivity of cervid PrP with PRC1 was unaffected by treatment with reducing agents, whereas PRC9 immunoreactivity was enhanced 1.5-fold (p < 0.05) following treatment of mouse PrP with βME (Fig. 6, A and B).

The conformational dependence of PRC5, PRC7, 6H4, and D18 recognition appeared incompatible with the ability of these mAbs to recognize PrP on Western blots, because PrP is generally regarded as denatured under these conditions (12, 13, 15, 18, 20–22). Furthermore, treatment of samples with guanidinium hydrochloride concentrations as high as 6 M prior to SDS-PAGE and immunoblotting failed to prevent PrP detection by PRC5 by Western blotting (Fig. 7C). To reconcile these discrepant observations, we hypothesized that, subsequent to denaturing treatments, PrP refolds during Western blotting to a structure amenable to detection by conformation-dependent antibodies. To address this hypothesis, we performed experiments in which membranes were denatured with 100 mM βME, 2% SDS at 55 °C for 30 min prior to immunoprobing with conformation-dependent or conformation-independent mAbs. In accordance with our expectations, recognition of mouse and elk PrP by the conformation-independent mAb POM2 (supplemental Fig. 1) was unaffected by post-Western denaturation, whereas the reactivities of conformation-dependent antibodies PRC5, PRC7, and 6H4 with mouse or elk PrP were consistently reduced compared with membranes not receiving post-transfer denaturing treatments (Fig. 7).
Reactivities of PRC mAbs with Mouse and Cervid PrP under Native Conditions—Antibody binding of PrP expressed on the surface of RK13 cells was monitored by FACS (supplemental Fig. 2,A and B), and the ability of mAbs to react with PrP in solution was monitored by immunoprecipitation (supplemental Fig. 2C). Measurements of the \( K_D \) values for mAb binding to immobilized mouse PrPSc expressed on the surface of RK13 cells by FACS and immunoprecipitated mouse and cervid PrP from brain homogenates of wild type and Tg(ElkPrP) mice, respectively. Measurements of the \( K_D \) values for PRC5 binding to immobilized mouse PrPSc by SPR gave values of \( 2.1 \times 10^{-6} \) and \( 9.1 \times 10^{-7} \), respectively. PRC1 efficiently recognized cervid but not mouse PrPSc by FACS and immunoprecipitation, and the \( K_D \) value for binding to recombinant cervid PrP was \( 7.0 \times 10^{-7} \). In contrast, PRC9 immunoprecipitated mouse but not elk PrP and recognized mouse PrPSc expressed on the surface of RK13 cells, but less strongly than PRC5 or 6H4. Accordingly, the \( K_D \) value for binding to mouse PrPSc was \( 1.2 \times 10^{-5} \). PRC7 also recognized cell surface expressed mouse and elk PrP but less efficiently than PRC5. Reflecting this, the \( K_D \) value for PRC7 binding to elk PrP was \( 1.7 \times 10^{-4} \). PRC7 failed to immunoprecipitate either species of PrPSc.

Involvement of Residues Required for mAb Binding on PrPSc Formation—Having confirmed the roles of specific amino acid residues in the epitopes of different PRC mAbs, we investigated the effects of mutations at these positions on the ability of either elk or mouse PrPSc to be converted into PrP(27–30). To address this, we infected RK13 cells stably expressing wild type and mutated versions of mouse or elk PrP with the respective species of prions, and we monitored the ability of mutated PrPSc to be converted to mouse or elk PrPSc(27–30). The effects of mutations of various epitope components depended on whether they were expressed in the context of mouse or elk PrP. For PRC5, mutation of either A133V or N162S inhibited conversion of elk PrPSc to PrPSc(27–30). In contrast, whereas mutation of A132V also inhibited conversion of mouse PrPSc to PrPSc(27–30), mutation of N158S did not inhibit conversion of mouse PrPSc to PrPSc, but instead it augmented PrPSc levels (Fig. 8B). In the case of PRC7, although mutation of Glu to Gln at mouse PrP residue 185 prevented conversion to PrPSc(27–30), mutation of Tyr at residue 154 to Asn had no impact on the ability of PrPSc to form protease-resistant PrP (Fig. 8C). Variable numbers of Gly residues immediately distal to mouse PrP Gln-90 controlled PrPSc (Fig. 8D). In contrast, deletion of a Gly residue in mouse PrP, which facilitated detection by PRC1 (Fig. 3C), abolished conversion to PrPSc (Fig. 8E). The effects of various epitope mutations on the ability of mouse and elk PrP to be converted to PrPSc(27–30) are summarized in Table 1.

**DISCUSSION**

**DNA Shuffling to Create Chimeric PrP**—We used a directed molecular evolutionary approach to create shuffled genes expressing novel PrP epitopes as immunogens. Our approach was based on previous studies that used DNA shuffling to produce chimeric envelope proteins capable of inducing neutralizing antibodies against all four dengue virus serotypes (33, 34) and to optimize immunogenicity and protective efficacy of Venezuelan equine encephalitis and type 1 human immunodeficiency virus envelope proteins (35, 36). Our strategy resulted in the isolation of mAbs that recognized cervid but not mouse PrP (PRC1) and mouse but not cervid PrP (PRC9), as well as antibodies that recognized both mouse and cervid PrP (PRC5 and PRC7). Not unexpectedly, all PRC mAbs had variable cross-reactivities with PrP from different species, although in the case of the PRC9, cross-reactivity was restricted to hamster PrP. The properties of epitopes recognized by these newly developed mAbs, as well as the known properties of previously characterized mAbs used in these studies, are detailed in Table 1.

**Characterization of Discontinuous Conformation-dependent PrP Epitopes**—In previous studies the lack of mAb binding to peptide fragments in ELISA led investigators to infer the existence of discontinuous PrP epitopes (15, 16). In the case of the IgM mAb 15B3, which has been used to selectively immunoprecipitate PrP aggregates in infectious prion disease (31), as well as a Tg mouse model of a genetically programmed prion disease (37), three distinct peptide sequences were found to react with 15B3 (human PrP amino acids 142–148, 162–170, and 214–226) (31). However, the direct involvement of specific amino acid residues in this, or any other conformation-dependent PrP epitope, has not been previously reported. Moreover, 15B3 and possibly other purported PrPSc-specific mAbs (38) have been shown to interact with noninfectious as well as infectious PrP aggregates (39), and additional studies provide evi-
Conformation-dependent PrP Epitopes

TABLE 1
Properties of novel epitopes raised against randomly shuffled chimeric PrP

<table>
<thead>
<tr>
<th>mAb</th>
<th>Elk PrP</th>
<th>Mouse PrP</th>
<th>Constitutive amino acids</th>
<th>Epitope characteristics</th>
<th>Conformation-dependent</th>
<th>Global domain</th>
<th>Effect of mutation on conversion of PrP\textsuperscript{Sc} to PrP\textsuperscript{Sc}</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRC1</td>
<td>7.0 × 10\textsuperscript{-7}</td>
<td>Gln-90</td>
<td>Linear</td>
<td>No</td>
<td>No</td>
<td>PrP\textsuperscript{3G}</td>
<td>Converts</td>
</tr>
<tr>
<td>PRC5</td>
<td>9.1 × 10\textsuperscript{-7}</td>
<td>Ala-132</td>
<td>Discontinuous</td>
<td>Yes</td>
<td>Yes</td>
<td>A152V</td>
<td>Converts</td>
</tr>
<tr>
<td>PRC7</td>
<td>1.7 × 10\textsuperscript{-4}</td>
<td>Tyr-154</td>
<td>Discontinuous</td>
<td>Yes</td>
<td>Yes</td>
<td>N158S</td>
<td>Converts</td>
</tr>
<tr>
<td>PRC9</td>
<td>1.2 × 10\textsuperscript{-5}</td>
<td>Tyr-224, Asp-226, Gly-227</td>
<td>Linear</td>
<td>No</td>
<td>No</td>
<td>ND</td>
<td>ND</td>
</tr>
</tbody>
</table>

Previously reported mAbs

<table>
<thead>
<tr>
<th>mAb</th>
<th>Description</th>
<th>Conformation</th>
<th>Effect of Mutation on</th>
</tr>
</thead>
<tbody>
<tr>
<td>6H4</td>
<td>Unknown, within 143–151</td>
<td>Linear</td>
<td>Yes</td>
</tr>
<tr>
<td>D18</td>
<td>Unknown, within 132–156</td>
<td>Discontinuous</td>
<td>Yes</td>
</tr>
<tr>
<td>R1</td>
<td>Unknown, within 224–230</td>
<td>Linear</td>
<td>No</td>
</tr>
<tr>
<td>HumP</td>
<td>Unknown, within 95–107</td>
<td>Linear</td>
<td>No</td>
</tr>
<tr>
<td>PCM2</td>
<td>Unknown, within 81–89</td>
<td>Linear</td>
<td>No</td>
</tr>
</tbody>
</table>

FIGURE 8. Effects of mutating PRC mAb epitopes on PrP\textsuperscript{Sc} formation. Western blots of extracts from RK13 cells expressing wild type and mutant PrP infected with CWD or RML prions. A and B, residues involved in the PRC5 epitope. C, residues involved in the PRC7 epitope. Mo N154, mouse PrP harboring mutation of Tyr to Asn at 154; Mo E185, mouse PrP harboring a mutation of Gln to Glu at 185; Mo N154/E185, mouse PrP harboring mutations of Tyr to Asn at 154 and Gln to Glu at 185. D–F, residues involved in the PRC1 epitope. Elk3G, elk PrP with three instead of two Gly residues; MoPrP\textsubscript{2G}, mouse PrP harboring two instead of three glycine residues; MoPrP\textsubscript{2G/RML}, infected with RML prions. Extracts were either treated (+) or not treated (−) with proteinase K (PK).

dence that 15B3 interactions with such aggregates are nonspecific and paratope-independent (40).

Our epitope mapping studies show that the highly conserved Ala residue at mouse PrP position 132, as well as the Asn at residue 158, contribute to recognition by mAb PRC5, whereas residues 154 and 185 are components of the PRC7 epitope. Because antibody paratopes are occupied at most by 15–22 amino acid antigen residues (41), the ∼30-residue separation between amino acid residues in each case unequivocally defines the epitopes of PRC5 and PRC7 as discontinuous.

Consistent with the conformational dependence of these discontinuous epitopes, we show that PRC5 and PRC7 immunoreactivity is reliant on the integrity of the disulfide bond linking α-helices 2 and 3, which stabilizes the tertiary structure of PrP. Our mutational analyses showing that recognition by PRC5, PRC7, 6H4, and D18 is inhibited exclusively by deletions disrupting the structured globular region are also consistent with our characterization of these epitopes as conformation-dependent. Our findings indicate that deletions invading any aspect of the structured globular domain, even sequence elements far removed from defined epitope components, destabilize the overall tertiary structure of the region, preventing correct epitope presentation for antibody recognition. In the case of mAb PRC5, Ala-132 and Asn-158 are adjacent in PrP tertiary structure at the base of the loop containing α-helix 1, which is formed during antiparallel juxtaposition of β-sheet regions 1 and 2 (Fig. 1B) (3). Disulfide bond disruption or destabilizing deletion mutations abolish the overall tertiary structure of the globular region, which in turn precludes residues 132 and 158 from acquiring the required proximity for PRC5 epitope forma-
Conformation-dependent PrP Epitopes

Because its epitope has been mapped to the region containing sequential amino acids DYEDRYRE corresponding to mouse PrP residues 143–151 (31), the behavior of mAb 6H4 indicates that linear as well as discontinuous epitopes within the structured globular domain exhibit conformational dependence, which is consistent with the previously observed behaviors of this mAb (20, 42). Previous studies showing loss of 6H4 immunoreactivity following PrP reduction and alkylation (22) were interpreted to mean that its epitope in $\alpha$-helix 1 became masked and therefore unavailable for detection. However, our results favor the alternative hypothesis that immunoreactivity of 6H4, and other mAbs with epitope components in this region, depends on correct local folding of $\alpha$-helix 1 and, moreover, that the sustained integrity of this secondary structural element is co-dependent on the overall tertiary structure of the globular domain.

In contrast to these conformation-dependent epitopes with the globular domain, the epitopes of PRC9, R1, HumP, and POM2, located in relatively unstructured regions proximal and distal to the globular region, are independent of PrP conformation for their recognition, because their ability to recognize PrP is unaffected by structure-disrupting deletions or by treatment with disulfide bond-reducing agents. Coincidentally, although deletion analysis has suggested a discontinuous epitope for anti-PrP mAb T2 (43), our results also indicate that mapping approaches relying exclusively on a lack of mAb binding to deletions within the structured domain of PrP (43) may lead to spurious interpretations of epitope locations.

Renaturation of Conformational PrP Epitopes—Our results shed light on previously reported difficulties surrounding anti-PrP mAb epitope mapping, which resulted in speculation that PrP may be idiosyncratically processed by antigen-presenting cells (12), or to inferences that the epitopes of such mAbs are discontinuous, and/or that peptide fragments in this format are unable to adopt specific conformations required for antibody binding (12–17). This latter hypothesis was rejected as highly unlikely (13), because all such antibodies bind PrP in Western blots, where PrP is defined by investigators as denatured (12, 13, 15, 18–22). Our discovery that mAbs PRC5 and PRP7, which recognize discontinuous conformation-dependent epitopes, react with wild type PrP on Western blots was also surprising. However, our findings indicate that, subsequent to denaturing treatments, PrP readily refolds during or after Western blotting to a structure amenable to detection by conformation-dependent antibodies. Although it is widely assumed that discontinuous epitopes are generally irreversibly destroyed under the denaturing conditions used for SDS-PAGE, positive reactions on Western blots with antibodies recognizing discontinuous epitopes are not without precedent (44).

Because PRC5, PRC7, and 6H4 also react with immuno-blotted PrP(27–30), our results demonstrate that PK-resistant PrP must also maintain the structural determinants required for recognition by these conformation-dependent mAbs. Our findings therefore indicate that, following denaturation, PrP$^{\text{C}}$ and PrP(27–30) re-nature into a common structure amenable to detection by conformation-dependent mAbs. However, recent studies using mass spectrometry analysis coupled with hydrogen-deuterium exchange indicate that PrP$^{\text{Sc}}$ consists of $\beta$-strands, relatively short turns, and/or loops, and no $\alpha$-helical structure, which represents a conformation radically different from PrP$^{\text{C}}$ (45). Our results therefore also suggest that the conformation of renatured PrP(27–30) is structurally more akin to PrP$^{\text{C}}$ than to PrP$^{\text{Sc}}$ from which it is derived.

PRC mAbs Discriminate PrP Polymorphisms and PrP Glycotypes—Epitopes of two of the four PRC mAbs are composed of PrP residues that are polymorphic and influence disease susceptibility in sheep and deer. PRC5 reactivity is dependent on the sheep Ala/Val polymorphism at residue 136. Susceptibility of sheep to classical scrapie is strongly associated with amino acid polymorphism at this residue, as well as polymorphisms at residues 154 and 171 (46). Although previous studies have shown mAbs to be capable of distinguishing OvPrP-Q171 and OvPrP-R171 allotypes (47, 48), the direct involvement of residue 171 in these epitopes was not demonstrated, and in the case of glycosylation-dependent antibodies, the effect was indirectly influenced by N-linked glycans on PrP(47). Recognition by PRC1 is also dependent on a known PrP polymorphism. Detection of deer PrP was inhibited when His replaced Glu at residue 95 but not when Ser replaced Gly at adjacent residue 96 (deer PrP numberings). These amino acid variations correspond to naturally occurring polymorphisms affecting susceptibility of white tail deer to CWD (49).

Monoclonal antibody PRC1 also fails to react with PrP primary structures containing three instead of two Gly residues immediately downstream of mouse PrP Glu-90. Our studies indicate that an additional Gly sterically hinders PRC1 recognition of its epitope, which includes Glu at mouse PrP residue 90/deer PrP residue 95. Other than deer harboring the H95 polymorphism, monoclonal antibody PRC1 has excellent reactivity with cervid PrP, and this specificity is therefore likely to be useful for studies on CWD. Like other mAbs with epitopes located at the boundary between the octarepeat region and the protease-resistant core of PrP(27–30) that have been used for molecular strain typing (13, 50–52), PRC1 may be useful for differentiating biochemically distinct forms of PrP(27–30) associated with different strains.

In addition to its conformational dependence, PRC7 immunoreactivity is also dependent of the state of glycosylation of PrP. Because PRC antibodies were derived from mice immunized with bacterially derived RecPrP, an N-linked glycan is unlikely to contribute to the PRC7 epitope. Instead, the preferential binding of PRC7 to under-glycosylated PrP suggests that occupancy of one of the two PrP N-linked glycosylation sites precludes antibody binding to the fully glycosylated protein, making it immunologically silent to PRC7. A similar mechanism has been suggested to explain the properties of previously isolated glycosylation-dependent antibodies (13, 19, 47).

PRC mAbs Expand the Range of Options for PrP Epitope Manipulation—The involvement of specific amino acids in mAb recognition has, to date, only been defined for a handful of mAbs, in particular 3F4 (53) and L42 (54). One application for which such information has proved useful is epitope tagging of...
Conformation-dependent PrP Epitopes

PrP molecules. Previous studies showed that PrP molecules engineered to include amino acid residues required for 3F4 binding could be converted to PrP\textsuperscript{Sc} in murine cell lines, chronically infected with adapted scrapie prions (24). Whereas such an approach is useful for assessing the effects of amino acid alterations on PrP\textsuperscript{Sc} formation, it is not without drawbacks, because 3F4 epitope inclusion can lead to interfering effects on PrP\textsuperscript{Sc} formation (55). In addition, the exact composition of the 3F4 epitope has been recently debated (56). Stable expression of PRC epitope-mutated PrP constructs in RK13 cells not only allowed us to confirm the requirement of those residues for recognition by various PRC mAbs but also to assess the effects of substitutions on conversion of PrP\textsuperscript{Sc}. Because RK13 cells support the replication of prions from a variety of species (29, 30, 57), we were able to assess the effects of these mutations on PrP\textsuperscript{Sc} formation in the context of multiple PrP primary structures. We found that mutation of amino acids constituting various PRC mAb epitopes had different effects on the abilities of mouse and cervid PrP to be converted to PrP\textsuperscript{Sc} (summarized in Table 1), which is consistent with previous observations that structural requirements for PrP\textsuperscript{Sc} conversion to protease-resistant PrP vary between PrP primary structures (58). Such information expands the available options for introducing new or eliminating existing PrP epitopes, while preserving the ability of mutated PrP\textsuperscript{C} to convert to PrP\textsuperscript{Sc}. For example, removal of one of three G\(\gamma\) residues after residue 90 preserved the ability of mutated mouse PrP to convert to PrP\textsuperscript{Sc} and facilitated recognition by PRC1. Similarly, mutation of mouse PrP at residues 158 and 154 preserved conversion to PrP\textsuperscript{Sc} and abolished recognition by mAbs PRC5 and PRC7, respectively. Such manipulations allow, for example, newly converted PrP\textsuperscript{Sc} to be distinguished from PrP\textsuperscript{Sc} in the inoculum and provide novel means of assessing the kinetics and cell biology of PrP\textsuperscript{Sc} formation.

In conclusion, we used a directed molecular evolution approach to create shuffled genes expressing novel PrP epitopes as immunogens. To our knowledge, these studies are the first to describe the involvement of specific amino acids in functional, discontinuous, and conformation-dependent anti-PrP mAb epitopes. We show that perturbations of the correct tertiary structure of the PrP globular domain, either by disulfide bond reduction or by the introduction of conformation-disrupting deletion mutants, affect the topology of a variety of conformational epitopes. We also show that conformation-dependent PrP epitopes readily reform following conditions of harsh denaturation, and that both PrP\textsuperscript{C} and PrP\textsuperscript{Sc} re-nature into a structure amenable to detection by conformation-dependent mAbs. The epitopes of two of the four new antibodies described here are composed of residues that are polymorphic in certain species and affect disease susceptibility in those hosts. Because of their dependence on these polymorphisms for reactivity, PRC1 and PRC5 represent unique immunological tools to assess the conversion and pathogenic effects of individual sheep and deer allotypes.\(^4\) Finally, the mapping and mutational analyses of PrP mAb epitopes described here not only expand the repertoire of available options for tagging PrP in Tg mice and transfected cell lines, but they also provide new information about the role of these amino acids in conversion of PrP\textsuperscript{C} to PrP\textsuperscript{Sc}.

Acknowledgments—We thank Tanya Seward for technical help during the early phase of these studies; Richard Bessen and Charles Merrill for critical reading of the manuscript; Stanley Prusiner for the kind gift of mAbs DJ8, R1, and HumP; Adriano Aguzzi for the kind gift POM2 mAb, and Prionics for mAb 6H4.

REFERENCES


\(^{4}\) E. Saijo and G. C. Telling, manuscript in preparation.

16. Williamson, R. A., Perez, D., Pinilla, C., Ball, H., Bastidas, R. B., Rosen- 
ping the prion protein using recombinant antibodies. J. Virol. 72, 
9413–9418.

17. Li, R., Liu, T., Wong, B. S., Pan, T., Morillas, M., Święcicki, W., O’Rourke, 
an epitope in the C terminus of normal prion protein whose expression is 

18. Khalili-Shirazi, A., Quarantino, S., Londei, M., Summers, L., Tayebi, M., 
conformation significantly influences immune responses to prion protein. 

S., Jackson, G. S., and Collinge, J. (2005) PrP glycoforms are associated in a 

transgene by immunoassays and transgenic mice. Vaccine 
27, 4152–4160.

vaccines yield monoclonal antibodies to cellular and pathological prion 

22. Yuan, J., Kinter, M., McGeehan, J., Perry, G., Kneale, G., Gambetti, P., and 
protein glycoforms from naturally occurring sheep scrapie, sheep-pas-
saged scrapie strains (CH1641 and SSBP1), bovine spongiform enceph-
alarthritis by inoculation with scrapie agent and its protection by 

23. Morel, N., Simon, S., Frobert, Y., Volland, H., Mourton-Gilles, C., Negro, 
A., Sorgato, M. C., Crémoin, C., and Grassi, J. (2004) Selective and effi-
cient immunoprecipitation of the disease-associated form of the prion 
protein can be mediated by nonspecific interactions between monoclonal 

on protein antigens. Misconceptions and realities. Cell 61, 
533–556.

25. Zanusso, G., Farinazzo, A., Prelli, F., Fiorini, M., Gelati, M., Ferrari, S., 
cation of distinct N-terminal truncated forms of prion protein in different 


27. Nazor, K. E., Fuhn, K., Seward, T., Muzzin, D., Püro, M., Schmitt, J., Biffiger, K., Power, A. M., Oesch, B., Raeber, A. J., and Telling, 
accelerates disease in GSS transgenic mice. EMBO J. 24, 2672–2480.

28. Pechs, B., Müller-Schifflmann, A., Lehle, A., Zirndum, I., Kuhn, F., 
effects and use of PrPSc- and PrP-specific antibodies generated by immu-
nization with purified full-length native mouse prions. J. Virol. 85, 
498, 72–74.

vaccines yield monoclonal antibodies to cellular and pathological prion 

30. Yuan, J., Kinter, M., McGeehan, J., Perry, G., Kneale, G., Gambetti, P., and 
Zou, W. Q. (2005) Concealment of epitope by reduction and alkylation in 


prion protein expression in cultured cells and transgenic mice. Protein 
Sci. 1, 986–997.

species amplification of PrP(CWD) and correlation with rigid loop 170N. 


35. Bilheude, J. M., Brun, A., Morel, N., Díaz San Segundo, F., Lecroix, S., 
Christensen, H. M., Satore, A., Chiesa, R., Williamson, R. A., and Harris, 

36. 2009) Characterization of discontinuous epitope of prion protein recognized by the 
epitope in the C terminus of normal prion protein whose expression is 

37. Nazor, K. E., Fuhn, K., Seward, T., Muzzin, D., Püro, M., Schmitt, J., Biffiger, K., Power, A. M., Oesch, B., Raeber, A. J., and Telling, 
accelerates disease in GSS transgenic mice. EMBO J. 24, 2672–2480.

38. Pechs, B., Müller-Schifflmann, A., Lehle, A., Zirndum, I., Kuhn, F., 
effects and use of PrPSc- and PrP-specific antibodies generated by immu-
nization with purified full-length native mouse prions. J. Virol. 85, 
498, 72–74.

vaccines yield monoclonal antibodies to cellular and pathological prion 

40. Yuan, J., Kinter, M., McGeehan, J., Perry, G., Kneale, G., Gambetti, P., and 
Zou, W. Q. (2005) Concealment of epitope by reduction and alkylation in 


prion protein expression in cultured cells and transgenic mice. Protein 
Sci. 1, 986–997.

acterization of discontinuous epitope of prion protein recognized by the 
epitope in the C terminus of normal prion protein whose expression is 

44. 2005) Characterization of discontinuous epitope of prion protein recognized by the 
epitope in the C terminus of normal prion protein whose expression is 

45. Smirnovas, V., Baron, G. S., Offerdal, D. K., Raymond, G. J., Caughey, B., 
and Surewicz, W. K. (2011) Structural organization of brain-derived 

46. Smirnovas, V., Baron, G. S., Offerdal, D. K., Raymond, G. J., Caughey, B., 
and Surewicz, W. K. (2011) Structural organization of brain-derived 
Conformation-dependent PrP Epitopes

lopathy (BSE) cases, and Romney and Cheviot breed sheep experimentally inoculated with BSE using two monoclonal antibodies. Acta Neuropathol. 104, 279–286


